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Abstract
We hypothesized that positive airway pressure treatment would induce nasal
obstruction and decrease nasal cavity due to mucosal swelling. We further hypothe-
sized that subjective and objective nasal obstruction at baseline would negatively
affect positive airway pressure adherence. A total of 728 patients with sleep apnea
were investigated in the Icelandic Sleep Apnea Cohort at baseline and 2 years after
starting positive airway pressure. Patients underwent home sleep apnea testing at
baseline. Questionnaires were answered and acoustic rhinometry was completed at
baseline and follow‐up. The proportion of patients reporting subjective nocturnal
nasal obstruction was reduced (baseline: 35% versus follow‐up: 24%; p < 0.001).
Small interior nasal dimensions increased (p < 0.001) independent of adherence to
treatment. Small nasal volume at baseline was a determinant for becoming a non‐
user of positive airway pressure treatment (odds ratio 2.22, confidence interval 95%
1.35–3.67, p = 0.002). Subjective nasal obstruction decreased 2 years after initiating
positive airway treatment in sleep apnea, and objectively small nasal dimensions
increased. Small nasal volume at baseline was a negative predictor for positive air-
way pressure treatment adherence. Maybe most importantly, positive airway pres-
sure treatment did not cause long‐term objective or subjective nasal obstruction.
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1 | INTRODUCTION
Nasal obstruction in patients with obstructive sleep apnea (OSA) is
common, and has an impact on quality of life and sleep quality (Vär-
endh et al., 2018). Some patients with OSA experience daytime
sleepiness and insomnia (Björnsdóttir et al., 2013). Patients with
OSA commonly have co‐morbidities, such as arterial hypertension
and cardiovascular disease (Ye et al., 2014).
Studies evaluating patients with OSA in the 1990s indicated that
positive airway pressure (PAP) treatment induced nasal side‐effects
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in 25%–64% of patients (Brander, Soirinsuo, & Lohela, 1999; Engle-
man et al., 1996; Hoffstein, Viner, Mateika, & Conway, 1992; Pépin
et al., 1995; Waldhorn et al., 1990), and most commonly increased
nasal obstruction (Kribbs et al., 1993). Kreivi, Virkkula, Lehto, and
Brander (2010) found a reduced proportion of patients reporting
nasal stuffiness after 2 months of PAP use. However, another study,
with the follow‐up time of 1 year, found that PAP induced nasal
stuffiness if not treated with heated humidification (Kreivi, Maasilta,
& Bachour, 2016).
Some studies have been investigating the histopathological
impact of PAP treatment on the nasal mucosa. Concerning the
mucosal structure, the ciliary transport does not seem to be changed
after 3 months of PAP treatment (Saka et al., 2012). There are con-
flicting results concerning the impact of PAP treatment on the
inflammatory response of the nasal mucosa. Saka et al. (2012) found
an increase in inflammatory cells after 3 months of PAP use, but on
the other hand Gelardi et al. (2012) showed that patients with OSA
using PAP had a reduction in inflammatory cells after 8 weeks of
treatment.
When focusing on the anatomical aspects, Iriz et al. (2017)
demonstrated a decrease in nasal dimensions measured with acous-
tic rhinometry (AR) after 1 month of PAP use, and a return to base-
line values after 3 months of PAP usage. Balsalobre et al. (2017) has
described immediate subjective and objective nasal blockage after 2
hr of PAP use. To our knowledge, the long‐term effect of PAP on
internal nasal dimensions has not been described, and no large, well‐
defined, prospective study has investigated the nose, either objec-
tively or subjectively. Our primary objective was to investigate the
long‐term effects of PAP treatment on subjective nasal obstruction
and objectively measured nasal dimensions. Moreover, we wanted to
determine whether subjective and objective nasal obstruction at
baseline influenced PAP adherence. We hypothesized that PAP
treatment induces nasal obstruction and decreases nasal cavity
due to mucosal swelling. We further hypothesized that subjective
and objective nasal obstruction at baseline negatively affects
PAP adherence.
2 | MATERIALS AND METHODS
2.1 | Study design and study subjects
The present study is a prospective cohort study, part of the Icelandic
Sleep Apnea Cohort (ISAC), as previously described (Arnardottir, Jan-
son, et al., 2013; Arnardottir, Maislin, et al., 2013). From September
2005 to December 2009, all patients with OSA in Iceland who were
referred for PAP treatment were invited to participate. For financial
reasons, patients underwent AR if follow‐up was performed before 1
September 2008. Hence, 419 patients underwent AR at follow‐up,
which was 78% of the patients who had follow‐up before 1 Septem-
ber 2008 (see Figure 1 for an outline of the included patients). The
ISAC study was approved by The National Bioethics Committee of
Iceland, the Data Protection Authority of Iceland, and the
Institutional Review Board of the University of Pennsylvania. All
patients signed a written informed consent.
2.2 | Measurements and questionnaires
At baseline, the patients answered the standardized questionnaires,
Epworth Sleepiness Scale (ESS; Björnsdóttir et al., 2012; Johns,
1991), Basic Nordic Sleep Questionnaire (BNSQ; Partinen & Gisla-
son, 1995) and the 12‐item Short‐Form Health Survey (SF‐12; Ware,
Kosinski, & Keller, 1996). Subjective nasal obstruction was examined
with the question: “Is your nose congested at night?” The responses
were categorized from 1 to 5: 1 = never or very seldom; 2 = less
than once a week; 3 = once–twice a week; 4 = three–five times a
week; and 5 = every night or almost every night of the week. A
score of 4 or 5 was defined as nocturnal nasal obstruction. The Basic
Nordic Sleep Questionnaire was used to examine symptoms of poor
sleep quality, including insomnia symptoms (Partinen & Gislason,
1995). Definitions of the insomnia subtypes – initial insomnia, middle
insomnia, and late insomnia (≥ 3 × per week) – have been described
previously (Björnsdóttir et al., 2012). The use of nasal and oral corti-
sone medication was also investigated (yes/no).
2.3 | Acoustic rhinometry
In AR, an acoustic pulse is sent into the nasal valves from the nos-
trils to provide an anatomical description with three‐dimensional
measurements of the nasal cavity (Clement & Gordts, 2005). A sin-
gle‐impulse rhinometer (Rhinoscan SRE2000, Rhinometrics, Assens,
Denmark) was used. The dimensions examined before and 15 min
after administration of the nasal spray oxymetazoline (0.5 mg ml−1;
two puffs per nostril) were: TMCA (total minimal cross‐section area
in the left and right nasal cavity); MCA‐min (the minimal cross‐sec-
tion area in either left or right nasal valve); TVOL (the total volume
of left and right nasal cavity); and TMCA‐diff (the difference
between TMCA before and after nasal decongestive spray). The
equipment was calibrated every morning prior to use. On all days of
examinations, some patients were examined in the morning (n = 2)
and some (n = 1) in the afternoon. One of the authors (MV) re‐evalu-
ated all AR results during 2–6 November 2015. Invalid measure-
ments at baseline (n = 3) and follow‐up (n = 4) were excluded.
2.4 | Sleep study
At baseline, patients underwent a home sleep apnea testing with an
Embletta portable monitor, an Embla 12‐channel system (EMBLATM;
Flaga, Reykjavik, Iceland) or a T3 device (Nox Medical, Reykjavik, Ice-
land; Arnardottir, Janson, et al., 2013; Arnardottir, Maislin, et al.,
2013; Björnsdóttir et al., 2012).
More than 4 hr of a scorable oxygen saturation (SaO2) signal was
required to include a sleep study. The apnea–hypopnea index (AHI)
was determined as the mean number of apnea and hypopnea per
hour of recording (upright time excluded). Apnea was defined as ≥
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80% decrease in flow for a period of ≥ 10 s. Hypopnea was defined
as ≥ 30% decrease in the flow with ≥ 4% oxygen desaturation, or ≥
50% decrease in flow for ≥ 10 s with an immediate increase in flow
at the end of the episode.
2.5 | Positive airway pressure
Patients received an auto‐adjusting PAP or continuous PAP device
(ResMed, San Diego, CA, USA; Arnardottir, Janson, et al., 2013;
Arnardottir, Maislin, et al., 2013; Björnsdóttir et al., 2012). In case of
problems with treatment efficacy, the treatment was changed to bi‐
level PAP (n = 17) or adaptive servo ventilation (n = 6). The definition
for inadequate treatment efficacy was AHI ≥ 15 events per hour
during PAP use. Patients had a choice of different masks and humid-
ifiers. From 2009 onwards, all PAP devices were delivered with
heated in‐line humidifiers.
Adherence of PAP at the 2‐year follow‐up was estimated from
memory cards or from a questionnaire (Arnardottir, Janson, et al.,
2013; Arnardottir, Maislin, et al., 2013. Full PAP usage was defined, in
mean, ≥ 20 days and ≥ 4 hr per night for the previous 4 weeks of
F IGURE 1 Flowchart showing the
patients included in subjective data and
objective data calculations respectively. A
total of 728 patients have answered the
question about nocturnal nasal obstruction
at both baseline and follow‐up. Four‐
hundred and nineteen patients have been
examined with acoustic rhinometry (AR)
both at baseline and at follow‐up
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machine‐derived data, or ≥ 5 nights per week for ≥ 60% of the night
by questionnaire. Subjects with less use were considered partial users.
Early quitters returned their devices within 1 year after treatment ini-
tiation, and late quitters kept the equipment for 365–729 days (Eys-
teinsdottir et al., 2017). Adherence data were missing in three cases.
2.6 | Nasal surgery
Data from patient files on the frequency of nasal surgery during the
2 years of study included septoplasty (n = 59), turbinectomy (n = 66),
and endoscopic surgery (n = 4). Patients with nasal surgery prior to
study start did not differ from the rest of the study sample with
respect to subjective or objective nasal obstruction, and were there-
fore not included in the group with nasal surgery.
2.7 | Statistical analysis
Nominal data are presented as frequencies and percentages without
decimals. The chi‐squared test was used in comparisons between
nominal data in independent groups. Differences over time were
tested using McNemar’s test. Quantitative data and ordinal data
were presented by means and standard deviations (± SD). Mann–
Whitney U‐test was used when calculating group differences for two
independent groups, and Kruskal–Wallis test for comparisons includ-
ing more than two groups. Post hoc analyses were calculated using
the Mann–Whitney U‐test. Paired samples were tested using the
Wilcoxon signed rank test. The enter method was used in the multi-
ple logistic regression analysis, and the method evaluates all the
covariate variables regardless of whether significant or not. Covari-
ates divided into more than two groups were categorized using the
last category containing the highest values as contrast. The statistical
software used was SPSS 23.0. A two‐sided p‐value < 0.05 was
considered significant.
3 | RESULTS
3.1 | General information
A flowchart showing the study cohort is shown in Figure 1. Subjec-
tive data were examined and reported for 728 patients, and objec-
tive data for 419 patients. No differences in age, gender, or
subjective nasal obstruction at baseline between the study sample
and the dropout group were observed (p = 0.26–0.91). General infor-
mation about the sample cohort is shown in Table 1. The women
had on average smaller nasal dimensions, lower weight and lower
physical quality of life than men. No sex differences in objective
nasal dimension change or in subjective nocturnal nasal obstruction
were found (Table S1). A few patients were on medications that can
influence nasal obstruction, including systemic corticosteroids at
baseline (1%) and at follow‐up (4%), nasal corticosteroids at baseline
(1%) and at follow‐up (5%), antihistamines (1%) and at follow‐up
(1%).
3.2 | Subjective and objective results at baseline
and follow‐up
The baseline data were published previously (Värendh et al.,
2018). The prevalence of subjective nocturnal nasal obstruction (≥
3 × per week) was 35% in the patients with OSA. Patients with
complaints of nasal obstruction had more daytime sleepiness (ESS:
12.5 ± 4.9 versus 10.8 ± 5.0; p < 0.001) and slightly lower mental
quality of life (SF‐12: 46.4 ± 11.4 versus 49.8 ± 10.5, p < 0.001)
than patients without nocturnal nasal obstruction. The minimum
cross‐section area within the smaller nasal valve prior to decon-
gestive spray was smaller in the patients with subjective nocturnal
nasal obstruction (0.42 ± 0.17 versus 0.45 ± 0.16 cm2, p = 0.013). In
the current study, the patients are divided into four groups
TABLE 1 Background data from baseline and 2‐year follow‐up comparing patients with and without objective data
All patients (n = 728) Patients with objective data (n = 419)
Baseline
2‐year
follow‐up
p‐value for group
difference Baseline
2‐year
follow‐up
p‐value for group
difference
Age (years; mean ± SD) 54.7 ± 10.4 56.8 ± 10.4 – 54.1 ± 10.3 56.1 ± 10.3 –
Female (%) 24 24 – 18 18 –
Never smoker (%) 27 28 1.00 27 28 0.52
Previous smoker (%) 52 52 50 50
Current smoker (%) 20 20 0.80 23 22 0.74
BMI (kg m−2) 33.5 ± 5.6 34.0 ± 5.8 <0.001 33.0 ± 5.6 33.5 ± 5.7 <0.001
Arterial hypertension (%) 58 59 0.36 55 55 1.00
Coronary heart disease, including
coronary heart occlusion, heart failure,
and/or stroke (%)
18 19 0.23 17 19 0.17
Diabetes (%) 11 13 0.006 11 12 0.23
Significance given in bold. Numbers given as mean ± SD if not specified, and p‐values when comparing mean values were calculated using the Wilcoxon
signed rank test. Independent groups shown with %, and when comparing nominal data the McNemar test was used.
BMI, body mass index.
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depending on subjective nocturnal nasal obstruction (Table 2).
Patients with nocturnal nasal obstruction at follow‐up were more
likely to have symptoms of poor quality of sleep, such as noctur-
nal sweating, insomnia and reduced physical quality of life inde-
pendent of their symptoms at baseline (p‐values < 0.02).
3.3 | Changes in subjective results over 2 years
Nocturnal nasal obstruction (≥ 3 × per week) decreased from 35% to
24% (p < 0.001) in the whole study group. When patients were divided
into groups depending on PAP adherence, there was a decrease in the
proportion of patients reporting subjective nocturnal nasal obstruction
between baseline and follow‐up in full users (p < 0.001), as well as in
early quitters (p = 0.005; Figure 2). There was no significant difference
in reported nocturnal nasal obstruction between the groups full user,
partial user, early quitter, and late quitter at baseline (p = 0.67) or at fol-
low‐up (p = 0.20; Table S2). The late quitters were few in number (seven
at baseline with nocturnal nasal obstruction and six at follow‐up).
3.4 | Changes in objective results over 2 years
All objective nasal dimensions increased on average after 2 years
(Tables 3 and S3). However, the reactivity of the nasal mucosa was
unchanged. This indicates that the increase in nasal dimensions was
not related to decongestion of the nasal mucosa. The reactivity did
not differ at the 2‐year follow‐up between the different groups of
PAP use (p = 0.94–0.97). Patients with a small total minimal cross‐
section area at baseline had an increase in dimensions at follow‐up
(p < 0.001), while no changes in dimensions were found in patients
with large total minimum cross‐section area at baseline (p = 0.65;
Figure 3). When comparing the group examined by AR with the
rest of the samples, no differences in age or weight (p = 0.07 and 0.20)
were found. However, the objectively examined patients had a slightly
lower body mass index (BMI; 33.6 ± 5.7 versus 34.5 ± 5.8 kg m−2,
p = 0.02).
3.5 | Relationship between subjective and objective
changes
The patients were divided into improved nocturnal nasal obstruction,
no change, and worse nocturnal nasal obstruction (Figure 4). There
were no significant differences in change in total minimal cross‐
section area over the 2 years. There was no relationship between the
groups with respect to changes in objective total minimal cross‐sec-
tion area (r = −0.02; p = 0.66 and 0.98). The group of patients with
more reported nocturnal nasal obstruction from baseline to follow‐up
TABLE 2 A larger proportion of the patients with nocturnal nasal obstruction at follow‐up had nocturnal sweating, nocturnal
gastroesophageal reflux, insomnia and impaired physical quality of life
Never
(n = 418)
Only at
baseline
(n = 134)
Only at 2‐year
follow‐up
(n = 52)
Both at baseline
and at
2‐year follow‐up
(n = 124)
p‐value for
group
difference
Underwent nasal surgery during the study 12% 25% 10% 15% 0.01
Nocturnal sweating, ≥ 3 × per week, 2 years 13% 14% 62% 25% 0.007
Nocturnal gastroesophageal reflux, ≥ 1 × per week, 2 years 5% 14% 8% 15% 0.002
Daytime sleepiness (ESS), 2 years 8.4 ± 4.6 8.6 ± 4.7 9.7 ± 4.2 8.8 ± 4.9 0.17
Initial insomnia, ≥ 3 × per week, 2‐year follow‐up 9% 16% 10% 18% 0.01
Middle insomnia, ≥ 3 × per week, 2 years 29% 39% 57% 44% 0.001
Late insomnia, ≥ 3 × per week, 2 years 18% 31% 35% 30% <0.001
SF‐12, Mental part, 2 years 51.7 ± 9.9 50.2 ± 10.8 49.1 ± 10.0 50.2 ± 10.5 0.16
SF‐12, Physical part, 2 years 43.4 ± 11.3 44.2 ± 10.7 42.4 ± 11.9 39.9 ± 11.4 0.01
Number of days on PAP 595.0 ± 241.1 593.2 ± 235.3 592.7 ± 223.9 573.4 ± 251.7 0.10
Hours of PAP use, last 28 days before 2 years (fu007; n =
203, missing 215) Objective data
6.17 ± 2.22 6.49 ± 1.67 5.47 ± 2.42 6.60 ± 1.88 0.10
Late quitters (n = 17) 2% 2% 4% 3% 0.41
Early quitters (n = 131) 18% 19% 15% 23%
Partial users (n = 199) 14% 8% 23% 15%
Full users (n = 480) 66% 71% 58% 63%
ESS, Epworth Sleepiness Scale; PAP, positive airway pressure; SF‐12, the 12‐Item Short‐Form Health Survey, a smaller version of the SF‐36v2 Health
Survey, measuring quality of life.
Significance given in bold. Mean values shown as mean ± SD and p‐values. Chi‐squared test when comparing proportions of groups here in %. Kruskal–
Wallis ANOVA when comparing ordinal data. Post hoc test (Mann–Whitney U‐test): subgroup analysis comparing the groups SF‐12, Physical part, 2
years, only baseline with both baseline and follow‐up, p‐value 0.18.
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also had an increase in internal nasal dimensions during the 2‐years
follow‐up (Table S4).
3.6 | The role of subjective and objective nasal
measurements at baseline in PAP adherence
Having subjective nocturnal nasal obstruction at baseline was not a
predictor of being a quitter within the first 2 years of use (Table 4).
On the other hand, having a small volume at baseline was a
determinant of becoming a non‐user of PAP after 2 years, compared
with having a large volume at baseline.
3.7 | Analysis of controller effects
3.7.1 | Subjective data
An analysis was completed with the subjective data with the follow-
ing groups excluded for each factor: nasal surgery, use of heated
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
Full user
(n = 264)
Paral user
(n = 99)
Early quier
(n = 131)
Late quier
(n = 17)
Nocturnal nasal obstrucon
baseline
Nocturnal nasal obstrucon 2
year follow-up
*** **
***p < 0.001, **p = 0.005
F IGURE 2 The proportion of patients
reporting subjective nasal obstruction
(≥ 3 × per week) at baseline compared
with follow‐up. There was a significant
(p ≤ 0.005) decrease in the proportion with
nocturnal nasal obstruction in full users
and early quitters. There was no significant
difference between the groups at baseline
(p = 0.67) or at follow‐up (p = 0.20). The
early quitters used their equipment for less
than 1 year. The late quitters used their
treatment for more than 1 year and less
than 2 years
TABLE 3 All objective nasal dimensions increased on average after 2 years except the reactivity of the nasal mucosa, which was unchanged
Baseline
2‐year
follow‐up
p‐value for group
difference
TMCA, total minimal cross‐section area in the nose, left and right nostril combined before nasal
decongestant spray (cm2)
1.06 ± 0.31 1.16 ± 0.33 <0.001
TMCA, total minimal cross‐section area in the nose, left and right nostril combined after
decongestant spray, (cm2)
1.24 ± 0.33 1.35 ± 0.32 <0.001
MCA‐min, smallest nasal valve of right and left, before decongestant spray (cm2) 0.43 ± 0.16 0.48 ± 0.17 <0.001
MCA‐min, smallest nasal valve of right and left after decongestant spray (cm2) 0.53 ± 0.17 0.58 ± 0.17 <0.001
TVOL, total volume of left and right nasal volume combined before nasal decongestant spray (cm3) 4.10 ± 0.82 4.37 ± 0.88 <0.001
TVOL, Total volume of left and right nasal volume combined mean after decongestant spray (cm3) 4.30 ± 0.84 4.61 ± 0.87 <0.001
Diff TMCA, difference between after and before decongestant spray (cm2), reactivity of the nasal
mucosa
0.19 ± 0.21 0.20 ± 0.24 0.61
Diff MCA‐min, smallest nasal valve of right and left, difference between after and before
decongestant spray (cm2), reactivity of the nasal mucosa
0.10 ± 0.12 0.10 ± 0.13 0.31
Diff TVOL, difference between after and before decongestant spray (cm3), reactivity of the nasal
mucosa
0.20 ± 0.34 0.24 ± 0.41 0.37
N = 419 at baseline and at follow‐up after 2 years.
Significance given in bold. Numbers given as mean ± SD if not specified, and p‐values when comparing mean values were calculated using the
Wilcoxon signed rank test. Nominal data in independent groups shown with %. The chi‐squared test was used for comparisons between nominal
data.
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humidifier, full‐face mask, mandibular advancement, or a >10%
weight decrease, respectively. None of the factors influenced the
findings based on subjective reports.
3.7.2 | Objective data
Analyses were also completed by assessing separately the objective
data in subjects having had nasal surgery (14% of the patients with
objective data), using a mandibular advancement device (8%), heated
humidifier (yes 36%/no 64%) and different mask type (full face 49%,
nasal 26% and pillow 7%). None of these factors influenced the
objective results. It was not possible to perform adequate calcula-
tions on weight decrease (> 10%) due to the lower number of
patients with objective measurements and weight decrease (eight
patients).
4 | DISCUSSION
This cohort study demonstrates that a significant number of patients
improved in subjective and objective nasal obstruction 2 years after
initiating PAP therapy. Patients with the smallest total minimal cross‐
section area at baseline had the largest increase in total minimal
cross‐section area. Subjective nasal obstruction at baseline did not
affect PAP adherence, while objective nasal obstruction at baseline
was a predictor for becoming a non‐user of PAP.
4.1 | Subjective and objective results at baseline
The baseline data have been published previously. In that study, we
reported that nasal obstruction is frequent and has an impact on
quality of life in patients with OSA (Värendh et al., 2018).
4.2 | Change in subjective nocturnal nasal
obstruction
In the present study, a significant proportion of the population expe-
rienced an improved nocturnal nasal obstruction. There was a
decrease in nocturnal nasal obstruction in the full users of PAP, but
also in the early quitters. It is challenging to speculate why the early
quitters also reported reduced nasal obstruction. However, it has
been shown recently that there is a decrease in symptoms in gen-
eral, even amongst non‐users to some extent (Pien et al., 2018).
Studies from the 1990s indicate an increase in nasal symptoms
with the PAP treatment regime that was used at that time (Brander
et al., 1999; Engleman et al., 1996; Hoffstein et al., 1992; Pépin
F IGURE 3 Patients with small total
minimal cross‐section area (TMCA) of left
and right nasal cavity before decongestant
spray, at baseline increase in TMCA
median (p ≤ 0.001) while patients with
large TMCA do not change, median in
boxplot (p = 0.65). x‐axis: 1 = smallest
TMCA at baseline up to 25% percentile (n
= 138); 2 = second smallest 26%–50% (n =
107); 3 = second largest percentile (n = 95);
4 = largest TMCA at baseline (n = 71). y‐
axis: TMCA (cm2). Wilcoxon signed rank
test was used when comparing change in
median
F IGURE 4 There was no difference between the groups of
subjective changes (improved, no change, more nasal obstruction) in
the objective changes in MCA‐min (p = 0.98, Kruskal–Wallis test)
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et al., 1995; Waldhorn et al., 1990). With more modern treatment,
including heated humidifiers, Kreivi et al. (2016) found that nasal
symptoms decrease upon therapy. However, in our study, patients
with heated humidification did not differ in nocturnal nasal obstruc-
tion to the patients without a humidifier.
It is possible that the new treatment regimens have been of
importance in improving the nasal symptoms developed during PAP
treatment. Another option is that the studies completed in the
1990s were not large follow‐up studies, and therefore did not
observe the resolution of nasal dimensions and symptoms. It could
be speculated that nasal symptoms are part of the OSA syndrome,
and that a successful treatment improving OSA also will improve
nasal symptoms associated with the disease itself.
4.3 | Change in objective nocturnal nasal obstruction
The nasal dimensions did not decrease upon PAP therapy, as we had
hypothesized; in contrast, nasal dimensions acutely increased. A
small study by Iriz et al. (2017) showed a decrease in minimal cross‐
section area after 1 month with PAP, while after 3 months on PAP
the area was back to baseline values. Another study by Balsalobre
et al. (2017) found more subjective and objective (AR) nasal obstruc-
tion immediately after 2 hr of PAP use in non‐OSA patients.
These observations indicate that there might be an initial swelling of
the nasal mucosa that lasts for the first month of PAP use due to the
pressure from the airflow. After 3 months, the mucosa adjusts, and after
2 years the nasal dimensions have improved. Two years after initiating
PAP treatment, we found that patients with small dimensions have the
biggest increases. It can be speculated that PAP treatment could affect
any interaction between afferent/efferent nasal tracheobronchial and
inspiratory muscle mechanoreceptors that participate in the coordina-
tion of inspiratory and expiratory efforts (McNicholas, Coffey, & Boyle,
1993). After interrupting the positive nasal air pressure ventilation treat-
ment, the nasal airflow resistance increased (Fontanari, Burnet, Zattara‐
Hartmann, Badier, & Jammes, 1999). Another option is a mechanical
widening of the nose by the nasal PAP mask or the air pressure. The
mechanisms are certainly of interest for further studies.
4.4 | Relationship between subjective and objective
changes
There was no relationship between improvements in subjective noc-
turnal obstruction and improvements in objective measurements
other than the fact that both improved. It is not clear whether there
is a relationship between subjective and objective nasal obstruction.
One review by André, Vuyk, Ahmed, Graamans, and Nolst Trenité
(2009) showed no strong evidence for a correlation between subjec-
tive and objective measurements or the opposite.
4.5 | The role of subjective and objective nasal
measurements at baseline in PAP adherence
Having a small volume at baseline was a predictor of becoming non‐ad-
herent to PAP treatment. In contrast, having self‐reported nocturnal
nasal obstruction at baseline was not predictive of becoming non‐adher-
ent to PAP treatment. This is in line with previous studies. Li et al. (2005)
found that in patients with small minimal cross‐section area at baseline,
the PAP adherence was lower after 3 months compared with patients
with large minimal cross‐section area. According to a study by Sugiura
et al. (2006), higher nasal resistance indicated lower odds ratio for accep-
tance of PAP treatment. Our findings indicate that having a small volume
at baseline indicates a higher risk that the patient will become non‐ad-
herent. There are many factors involved when patients become non‐ad-
herent to PAP treatment, and nasal obstruction can be one of the
reasons, at least for the patients quitting early in the treatment. It is pos-
sible that subjective nasal obstruction can be improved by PAP adher-
ence, while the objective nasal obstruction should be treated surgically.
4.6 | Strength and limitations of the study
The main strength of the study is that the results are based on a
well‐defined, large group of patients with OSA prior to and 2 years
after initiating PAP treatment.
The main concern is that there is no control group to prove causal-
ity between PAP use and the improved subjective or objective nasal
TABLE 4 Having a small volume at baseline was a predictor of becoming a non‐user of PAP after 2 years compared with having a large
volume at baseline
Unadjusted
odds ratio (95% CI)
p‐value
for group difference
Adjusted
odds ratio (95% CI)
p‐value for
group difference
Nocturnal nasal obstruction at baseline, ≥ 3 × per week 1.11 (0.79–1.57) 0.55 1.18 (0.80–1.74) 0.42
TMCA percentiles at baseline, comparing the smallest
quartile with the largest
1.80 (1.11–2.93) 0.02 0.35 (0.07–1.83) 0.22
TVOL, percentiles at baseline, comparing the smallest
quartile with the largest
2.22 (1.35–3.67) 0.002 3.31 (1.07–10.26) 0.04
MCA‐min, percentiles at baseline, comparing the smallest
quartile with the largest
1.80 (1.08–3.00) 0.02 2.01 (0.48–8.47) 0.34
The table shows the prediction of PAP non‐use (early and late quitters) depending on subjective and objective nasal obstruction at baseline. Included in
this analysis: auto‐adjusting PAP, continuous PAP device and adaptive servo ventilation. Significance in bold. Multiple regression analysis was used.
Odds ratio adjusted for age, BMI and AHI at baseline.
CI, confidence interval; MCA‐min, minimal cross‐sectional area within the smallest nostril of either left or right before decongestant spray; TMCA, total
minimal cross‐section area in the nose, left and right nostril combined before nasal decongestant spray; TVOL, total volume of left and right nasal
volume combined before nasal decongestant spray.
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obstruction. There were only nine patients without any PAP use at all,
and with such a small group it is not possible to draw any conclusions.
Other limitations include not having a full polysomnography, but
rather home sleep apnea testing, which evaluates breathing rather
than sleep.
Subjective data have limitations, and self‐reported PAP use was
used in the early home sleep apnea testing studies when objective
data were not available. However, self‐reported data have, in a
previous study, demonstrated 98.6% sensitivity and 45.1% specificity
in separating full users from partial users of PAP treatment (Björns-
dottir et al., 2015). There is another concern on subjective data in
regard to nasal obstruction in relation to PAP. However, when inves-
tigating the differences in nasal obstruction between groups with
different levels of PAP adherence, subjective data were chosen as
no relation was found between objective data and level of PAP use.
The nasal cycle has an influence on nasal dimensions with varia-
tions within hours, which could be argued to limit the objective AR
results. The effect of the nasal cycle is limited by adding the two valves
together in TMCA. In terms of the parameter MCA‐min, the results are
consistent with the other parameters. When finding improvements in
nasal dimensions in a large population over a time of 2 years apart
with p‐values of < 0.001, we believe that the impact of the nasal cycle
on the results in the current study is most likely restricted.
It would have been interesting to perform AR during sleep and
in the supine position, but this is not possible to achieve. One limita-
tion could also be regression to the mean in terms of the smaller
minimal cross‐section areas becoming larger after 2 years.
4.7 | What is new? Clinical implications
The findings that nasal subjective and objective obstruction improve
2 years after the treatment start are of clinical interest when inform-
ing patients at the beginning of the PAP treatment.
Subjective nasal obstruction can be improved by adherence to PAP
treatment, while patients with objective nasal obstruction should possi-
bly be offered surgical treatment prior to initiating PAP treatment.
5 | CONCLUSIONS
Subjective nasal obstruction improved 2 years after initiating PAP
treatment for sleep apnea. There was an objective improvement,
especially in patients with small nasal dimensions. Objectively small
nasal volume at baseline was a predictor for becoming a non‐user of
PAP. And, primarily, PAP treatment did not cause long‐term objec-
tive or subjective nasal obstruction.
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